3349 — Cosmos Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedLarge CapNeutral

Annual income statement for Cosmos Pharmaceutical, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st	2025 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	—	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	726,424	755,414	827,697	964,989	1,011,390
Cost of Revenue
Gross Profit	145,111	151,448	168,718	188,306	213,281
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	694,706	725,696	797,882	934,143	971,774
Operating Profit	31,718	29,718	29,815	30,846	39,616
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	38,596	33,048	32,773	33,719	42,372
Provision for Income Taxes
Net Income After Taxes	27,157	23,156	23,798	24,454	30,979
Net Income Before Extraordinary Items
Net Income	27,157	23,156	23,798	24,454	30,979
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	27,156	23,155	23,797	24,454	30,978
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	318	291	303	314	398
Dividends per Share